Biomarker panel for diagnosis or prediction of brain metastasis of lung cancer, and use thereof
AssigneesThe Catholic University of Korea Industry-Academic Cooperation Foundation, Samsung Life Public Welfare Foundation
InventorsHae-Ock LEE, Myung-Ju AHN, Na Young KIM
Life of this patent
Estimating the term…
Abstract
The present invention relates to a biomarker panel for the diagnosis or prediction of brain metastasis of lung cancer and a method for the diagnosis or prediction of metastatic brain tumors by using the panel. Accuracy and sensitivity in diagnosing lung cancer brain metastases were improved by providing a biomarker screened from pure tumor cells, beyond the limitations of biomarkers screened on the basis of bulk data of mixed tumor cells and cancer microenvironment cells.
Claims13
A biomarker panel for the diagnosis or prediction of brain metastasis of lung cancer, comprising an agent for measuring the levels of two or more biomarkers selected from the group consisting of fibronectin 1 (FN1), macrophage migration inhibitory factor (MIF), perilipin 2 (PLIN2), Kruppel like factor 6 (KLF6), phosphofructokinase, platelet (PFKP), biliverdin reductase B (BLVRB), SRY-box transcription factor 4 (SOX4), glycogen phosphorylase L (PYGL), inositol monophosphatase 2 (IMPA2), and vascular endothelial growth factor A (VEGFA).
A biomarker panel for the diagnosis or prediction of brain metastasis of lung cancer, comprising an agent for measuring the levels of two or more biomarkers selected from the group consisting of microsomal glutathione S-transferase 1 (MGST1), neugrin (NGRN), member RAS oncogene family (RAB11A), mortality factor 4 like 1 (MORF4L1), SMAD family member (SMAD9), lipoma HMGIC fusion partner L6 (LHFPL6), methenyltetrahydrofolate synthetase (MTHFS), mitochondrial ribosomal protein L18 (MRPL18), and peptidase D (PEPD).
A method of screening a biomarker for the diagnosis or prediction of brain metastatic lung cancer, comprising:
- performing single-cell transcriptome analysis on lung cancer samples separated from a lung cancer patient with brain metastasis and a lung cancer patient without brain metastasis;
- identifying tumor cells showing amplification of copy number variations (CNVs) through data obtained by the single-cell transcriptome analysis;
- and
- screening proteins or genes encoding the same, which show a difference in expression between tumor cells derived from the lung cancer patient with brain metastasis and tumor cells derived from the lung cancer patient without brain metastasis at a single-cell level or pseudo-bulk level for the identified tumor cells.
A method for the diagnosis or prediction of brain metastasis of lung cancer, comprising:
- measuring the levels of two or more biomarkers selected from the group consisting of fibronectin 1 (FN1), macrophage migration inhibitory factor (MIF), perilipin 2 (PLIN2), Kruppel like factor 6 (KLF6), phosphofructokinase, platelet (PFKP), biliverdin reductase B (BLVRB), SRY-box transcription factor 4 (SOX4), glycogen phosphorylase L (PYGL), inositol monophosphatase 2 (IMPA2), and vascular endothelial growth factor A (VEGFA) in a sample isolated from a subject;
- and
- comparing the levels of the biomarkers with the corresponding results of the markers in a control sample.
A method for the diagnosis or prediction of brain metastasis of lung cancer, comprising:
- measuring the levels of two or more biomarkers selected from the group consisting of microsomal glutathione S-transferase 1 (MGST1), neugrin (NGRN), member RAS oncogene family (RAB11A), mortality factor 4 like 1 (MORF4L1), SMAD family member (SMAD9), lipoma HMGIC fusion partner L6 (LHFPL6), methenyltetrahydrofolate synthetase (MTHFS), mitochondrial ribosomal protein L18 (MRPL18), and peptidase D (PEPD) in a sample isolated from a subject;
- and
- comparing the levels of the biomarkers with the corresponding results of the markers in a control sample.
Dependencies are inferred from the claim text.